1. Home
  2. People
  3. Bloxham, Laura Rose

Laura Rose Bloxham

Partner

Seattle

Laura represents high growth technology and life sciences companies from inception to exit. She advises entrepreneurs in company formation, venture capital financing, and a variety of corporate and governance matters.

Laura is a founding member of Orrick’s technology companies practice in the Pacific Northwest. She is passionate about working with founders to grow their business at every stage. She serves as a trusted advisor to her clients in multiple capacities: providing strategic advice in the boardroom, designing and executing financing strategies, negotiating complex transactions from venture financings to successful exits, and supporting day-to-day legal needs of executive teams.

She represents companies and their investors in a variety of verticals, including automotive and logistics (Civil Maps, Convoy, Getaround), consumer applications (AppSheet, Life360, Mylio), financial technology (Credible Labs, Ladder Financial, SoFi), information security (Critical Informatics, Zimperium) and life sciences (Cortexyme, Inmedix), among others.

Prior to joining Orrick, Laura worked in New York as a leveraged finance attorney at Milbank, and in-house at Goldman Sachs and the New York Stock Exchange. In addition to start-up representation, she regularly provides pro bono legal advice to charitable organizations regarding non-profit incorporation and tax exemption applications.

    Amber.io (d/b/a Two Tap)
    • $9.5 million sale to Honey
    Appsheet
    • $19.3 million Series A financing
    • Acquisition by Google
    BoomTV
    • $8.8 million Series A financing
    CelLink 
    • $22.5 million Series B financing
    CI Security
    • $6.4 million Series A financing
    • $16 million Series B financing
    Convoy
    • $185 million Series C financing
    • $400 million Series D financing
    Cortexyme
    • $76.9 million Series B financing
    • $75 million IPO on NASDAQ
    Credible
    • $50.9 million IPO on ASX
    Curebase
    • $2.5 million Series Seed financing
    Getaround 
    • $300 million Series D financing
    • $300 million acquisition of Drivy
    Grabango
    • $18.1 million Series A financing
    Ladder Financial
    • $30 million Series B financing
    Life360
    • $28 million Series D financing
    • $120.1 million IPO on ASX
    M12
    • $230 million Series C investment in Psiquantum
    • $70 million Series F investment in BlueVine
    • $10 million Series B investment in Skedulo Holdings, Inc
    • $25 million Series B investment in Syntiant
    Oisin Biotechnologies
    • $3 million Safe financing
    OncoSenX
    • $3 million Seed financing
    Social Finance (d/b/a SoFi)
    • General corporate advisement on its $1.2 billion acquisition of Galileo
    Solfice Research (d/b/a Civil Maps)
    • $9.4 million Series A financing
    Varian Medical Systems
    • $140 million Series B investment in Fusion Pharmaceuticals